The future of D-cycloserine and other cognitive modifiers in obsessive-compulsive and related disorders

Current Psychiatry Reviews

Volumn 10, Issue 4, 2014, Pages 317-324

  Sulkowski, Michael L ^a   Geller, Daniel A ^b   Lewin, Adam B ^c   Murphy, Tanya K ^c,d   Mittelman, Andrew ^b   Brown, Ashley ^b   Storch, Eric A ^c,d  

^a UNIVERSITY OF ARIZONA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Brain derived neurotrophic factor; Cognitive enhancer; D cycloserine; Glucocorticoids; Memory reconsolidation; Obsessive compulsive disorder; Yohimbine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOSTERONE; CYCLOSERINE; HYDROCORTISONE; NOOTROPIC AGENT; YOHIMBINE;

AEROBIC EXERCISE; AGORAPHOBIA; ANXIETY; ARTICLE; DECLARATIVE MEMORY; FEAR; HUMAN; LEARNING; MEMORY CONSOLIDATION; MONOTHERAPY; NERVE CELL PLASTICITY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOCIAL PHOBIA; VIRTUAL REALITY EXPOSURE THERAPY;

EID: 84926348580     PISSN: 15734005     EISSN: 18756441     Source Type: Journal    
DOI: 10.2174/1573400510666140619224942     Document Type: Article

References (75)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Fourth Edition, Text Revision. American Psychiatric Publishing, Inc: 2000.
2. Angst J, Gamma A, Endrass J, Goodwin R, Ajdacic V, Eich D, Rossler W. Obsessive-compulsive severity spectrum in the community: Prevalence, comorbidity, and course. Eur Arch Psychiatry Clin Neurosci 2004; 254(3): 156-64.
3. Sulkowski ML, Mariaskin A, Storch EA. Obsessive-compulsive spectrum disorder symptoms in college students. J Am Coll Health 2011; 59(5): 342-8.
4. Sulkowski ML, Mariaskin A, Jordan C, Storch EA. In: Lassiter G, Ed. Impulsivity: Causes, control and disorders. Hauppauge: NY Nova Publishers. 2009; pp. 31-58.
5. Keeley ML, Storch EA, Merlo LJ, Geffken GR. Clinical predictors of response to cognitive-behavioral therapy for obsessivecompulsive disorder. Clin Psychol Rev 2008; 28(1): 118-30.
6. Pallanti S, Quercioli L. Treatment-refractory obsessive-compulsive disorder: Methodological issues, operational definitions and therapeutic lines. Prog Neuro-Psychopharmacol Biol Psychiatry 2006; 30(3): 400-12.
7. de Haan. Effective treatment of OCD? J Am Acad Child Adolesc Psychiatry 2006; 45(4): 382-3.
8. Tolin DF. In: Steketee, G. Ed. The Oxford handbook of obsessive compulsive and spectrum disorders 2011; pp. 365-85.
9. Hofmann SG, Sawyer AT, Korte KJ, Smits JAJ. Is it beneficial to add pharmacotherapy to cognitive-behavioral therapy when treating anxiety disorders? A meta-analytic review. Int J Cogn Ther 2009; 2(2): 160-8.
10. McNally RJ. Mechanisms of exposure therapy: How neuroscience can improve psychological treatments for anxiety disorders. Clin Psychol Rev 2007; 27(6): 750-9.
11. Norberg MM, Gilliam CM, Villavicencio A, Pearlson GD, Tolin DF. D-cycloserine for treatment nonresponders with obsessivecompulsive disorder: A case report. Cogn Behav Prac in press.
12. Byrne SP, Farrell LJ, Rapee RM. Using cognitive enhancers to improve the treatment of anxiety disorders in young people: Examining the potential for D-cycloserine to augment exposure for child anxiety. Clin Psychol 2011; 15(1): 1-9.
13. Hofmann SG, Smits JAJ, Asnaani A, Gutner CA, Otto MW. Cognitive enhancers for anxiety disorders. Pharmacol Biochem Behav 2011; 99(2): 275-84.
14. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatr 2004; 61(11): 1136-1144.
15. Maren S. Seeking a spotless mind: Extinction, deconsolidation, and erasure of fear memory. Neuron 2011; 70(5): 830-45.
16. Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessivecompulsive disorder. Psychopharmacology 2006; 184(2): 254-256.
17. Grant JE, Kim SW, Odlaug BL. N-acetyl cysteine, a glutamatemodulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatr 2007; 62(7): 652-657.
18. Harvey BH, Brink CB, Seedat S, Stein DJ. Defining the neuromolecular action of myo-inositol: Application to obsessivecompulsive disorder. Prog Neuropsychopharmacol Biol Psychiatr 2002; 26(1): 21-32.
19. Cox J, Westbrook R. The NMDA receptor antagonist MK-801 blocks acquisition and extinction of conditioned hypoalgesic responses in the rat. Q J Exp Psychol B 1994; 47(2): 187-210.
20. Ledgerwood L, Richardson R, Cranney J. Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 2003; 117: 341-9.
21. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of Dcycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatr 2011; 50(5): 451-9.
22. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in xenopus oocytes. Brain Res 1990; 510(1): 158-60.
23. Krystal JH. Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: New opportunities for synergy with psychotherapy. Biol Psychiatr 2007; 62(8): 833-4.
24. Hofmann SG, Pollack MH, Otto MW. Augmentation treatment of psychotherapy for anxiety disorders with D-ycloserine. CNS Drug Rev 2006; 12(3-4): 208-17.
25. Siegmund A, Golfels F, Finck C, Halisch A, Raeth D, Plag J, Strohle A. D-cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res 2011; 45(8): 1042-7.
26. Chasson GS, Buhlmann U, Tolin DF, Rao SR, Reese HE, Rowley T, Welsh KS, Wilhelm S. Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine. Behav Res Ther 2010; 48(7): 675-9.
27. Hofmann SG, Meuret AE, Smits JAJ, Simon NM, Pollack MH, Eisenmenger K, Shiekh M, Otto MW. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63(3): 298-394.
28. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, Dadds MR. A randomized controlled trial of Dcycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63(6): 544-9.
29. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, Hofmann SG, Eisenmenger K, Krystal JH, Pollack MH. Efficacy of D-cycloserine for enhancing response to cognitivebehavior therapy for panic disorder. Biol Psychiatry 2010; 67(4): 365-70.
30. Guastella AJ, Dadds MR, Lovibond PF, Mitchell P, Richardson R. A randomized controlled trial of the effect of D-cycloserine on exposure therapy for spider fear. J Psychiatr Res 2007; 41(6): 466-71.
31. Ost LG, Ferebee I, Furmark T. One-session group therapy of spider phobia: Direct versus indirect treatments. Behav Res Ther 1997; 35(8): 721-32.
32. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62(8): 835-8.
33. Wilhelm S, Buhlmann U, Tolin D, Meunier S, Pearlson G, Reese H, Cannistraro P, Jenike M, Rauch S. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165(3): 335-41.
34. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, Jacob ML, Larson M, Hirsh A, Fernandez M. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007; 22(4): 230-7.
35. Storch EA, Murphy TK, Goodman WK, Geffken GR, Lewin AB, Henin A, Micco JA, Sprich S, Wilhelm S, Bengtson M. A preliminary study of D-cycloserine augmentation of cognitivebehavioral therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2010; 68(11): 1073-6.
36. Scahill L, Riddle MA, McSwiggin-Hardin M, Ort SI, King RA, Goodman WK, Cicchetti D, Leckman JF. Children’s Yale-Brown Obsessive Compulsive Scale: Reliability and validity. J Am Acad Child Adolesc Psychiatry 1997; 36(6): 844-52.
37. Barsky AJ, Ahern DK. Cognitive behavior therapy for hypochondriasis. JAMA 2004; 291(12): 1464-70.
38. Cororve MB, Gleaves DH. Body dysmorphic disorder: A review of conceptualizations, assessment, and treatment strategies. Clin Psychol Rev 2001; 21(6): 949-70.
39. McKay D. Two-year follow-up of behavioral treatment and maintenance for body dysmorphic disorder. Behav Modif 1999; 23(4): 620-9.
40. Neziroglu F, McKay D, Todaro J, Yaryura-Tobias JA. Effect of cognitive behavior therapy on persons with body dysmorphic disorder and comorbid axis II diagnoses*. Behav Ther 1997; 27(1): 67-77.
41. Visser S and Bouman TK. The treatment of hypochondriasis: Exposure plus response prevention vs. cognitive therapy. Behav Res Ther 2001; 39(4): 423-42.
42. Stein DJ and Lochner C. Obsessive-compulsive spectrum disorders: A multidimensional approach. Psychiatr Clin North Am 2006; 29(2): 343-51.
43. Storch EA, Abramowitz J, Goodman WK. Where does obsessivecompulsive disorder belong in DSM-V? Depress Anxiety 2008; 25(4): 336-47.
44. Bienvenu OJ, Samuels JF, Riddle MA, Hoehn-Saric R, Liang KY, Cullen BA, et al. The relationship of obsessive-compulsive disorder to possible spectrum disorders: results from a family study. Biol Psychiatry 2000; 48: 287-93.
45. MA, Nestadt G. The relationship of obsessive-compulsive disorder to possible spectrum disorders: Results from a family study. Biol Psychiatr 2000; 48(4): 287-93.
46. Jaisoorya T, Reddy Y, Srinath S. The relationship of obsessivecompulsive disorder to putative spectrum disorders: Results from an Indian study. Compr Psychiatr 2003; 44(4): 317-23.
47. Bohne A, Wilhelm S, Keuthen NJ, Florin I, Baer L, Jenike MA. Prevalence of body dysmorphic disorder in a German college student sample. Psychiatr Res 2002; 109(1): 101-4.
48. Beckner VE, Tucker DM, Delville Y, Mohr DC. Stress facilitates consolidation of verbal memory for a film but does not affect retrieval. Behav Neurosci 2006; 120(3): 518-27.
49. Otto MW, McHugh RK, Kantak KM. Combined pharmacotherapy and Cognitive_Behavioral therapy for anxiety disorders: Medication effects, glucocorticoids, and attenuated treatment outcomes. Clin Psychol 2010; 17(2): 91-103.
50. Bentz D, Michael T, de Quervain DJF, Wilhelm FH. Enhancing exposure therapy for anxiety disorders with glucocorticoids: From basic mechanisms of emotional learning to clinical applications. J Anxiety Disord 2010; 24(2): 223-30.
51. Soravia LM, Heinrichs M, Aerni A, Maroni C, Schelling G, Ehlert U, Roozendaal B, Dominique JF. Glucocorticoids reduce phobic fear in humans. PNAS 103(14): 5585-90.
52. de Quervain DJF, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, Wilhelm FH. Glucocorticoids enhance extinction-based psychotherapy. PNAS 2011; 108(16): 6621-6.
53. Gerardi M, Rothbaum BO, Astin MC, Kelley M. Cortisol response following exposure treatment for PTSD in rape victims. J Aggression Maltreat Trauma 2010; 19(4): 349-56.
54. Siegmund A, Koster L, Meves AM, Plag J, Stoy M, Strohle A. Stress hormones during flooding therapy and their relationship to therapy outcome in patients with panic disorder and agoraphobia. J Psychiatr Res 2011; 45(3): 339-46.
55. Holmes A, Quirk GJ. Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders-the case of yohimbine. Trends Pharmacol Sci 2010; 31(1): 2-7.
56. Powers MB, Smits JAJ, Otto MW, Sanders C, Emmelkamp PMG. Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: A randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 2009; 23(3): 350-6.
57. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: Biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987; 144(8): 1030-1036.
58. Meyerbroeker K, Powers M, van Stegeren A, Emmelkamp P. Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? A randomized placebo-controlled trial. Psychother Psychosom 2012; 81(1): 29-37.
59. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112(2): 257-69.
60. Kobayashi K, Shimizu E, Hashimoto K, Mitsumori M, Koike K, Okamura N, Koizumi H, Ohgake S, Matsuzawa D, Zhang L. Serum brain-derived neurotrophic factor (BDNF) levels in patients with panic disorder: As a biological predictor of response to group cognitive behavioral therapy. Prog Neuro-Psychopharmacol Biol Psychiatry 2005; 29(5): 658-63.
61. Berchtold NC, Castello N, Cotman CW. Exercise and timedependent benefits to learning and memory. Neuroscience 2010; 167(3): 588-97.
62. Cotman CW and Berchtold NC. Exercise: A behavioral intervention to enhance brain health and plasticity. Trends Neurosci 2002; 25(6): 295-301.
63. Strohle A, Stoy M, Graetz B, Scheel M, Wittmann A, Gallinat J, Lang UE, Dimeo F, Hellweg R. Acute exercise ameliorates reduced brain-derived neurotrophic factor in patients with panic disorder. Psychoneuroendocrinology 2010; 35(3): 364-8.
64. Ji JZ, Wang XM, Li BM. Deficit in long-term contextual fear memory induced by blockade of β-adrenoceptors in hippocampal CA1 region. Eur J Neurosci 2003; 17(9): 1947-52.
65. Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, Cahill L, Orr SP. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002; 51(2): 189-92.
66. Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK. Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder. J Psychiatr Res 2008; 42(6): 503-6.
67. Pitman RK. Will reconsolidation blockade offer a novel treatment for posttraumatic stress disorder? Front Behav Neurosci 2011; 5(11): 1-2.
68. Schiller D, Monfils MH, Raio CM, Johnson DC, LeDoux JE, Phelps EA. Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 2009; 463(7277): 49-53.
69. Abercrombie HC, Speck NS, Monticelli RM. Endogenous cortisol elevations are related to memory facilitation only in individuals who are emotionally aroused. Psychoneuroendocrinology 2006; 31(2): 187-96.
70. Pitman RK. Post-traumatic stress disorder, hormones, and memory. Biol Psychiatry 1989; 26(3): 221-3.
71. Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, Marmar CR. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003; 54(9): 947-9.
72. Nader K, Hardt O. A single standard for memory: The case for reconsolidation. Nat Rev Neurosci 2009; 10(3): 224-34.
73. Kindt M, Soeter M, Vervliet B. Beyond extinction: Erasing human fear responses and preventing the return of fear. Nat Neurosci 2009; 12(3): 256-8.
74. Bouton ME. Context, time, and memory retrieval in the interference paradigms of Pavlovian learning. Psychol Bull 1993; 114(1): 80-99.
75. Foa EB, Kozak MJ. Emotional processing of fear: Exposure to corrective information. Psychol Bull 1986; 99(1): 20-35.